NewAmsterdam Pharma (NAMS) News Today $23.55 +0.13 (+0.56%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9% - Should You Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.9% - What's Next?January 16 at 2:23 PM | marketbeat.comNewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks NowJanuary 15 at 4:50 PM | insidermonkey.comPromising Outlook for NewAmsterdam Pharma: Ed Arce’s Buy Rating Backed by Strategic Developments and Phase 3 SuccessesJanuary 14 at 6:46 PM | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday.January 14 at 8:05 AM | marketbeat.comNewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2024 and outlJanuary 12, 2025 | americanbankingnews.comNewAmsterdam Pharma outlines 2025 strategic prioritiesJanuary 11, 2025 | markets.businessinsider.comNewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesJanuary 10, 2025 | gurufocus.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options and Restricted Stock Units ...January 9, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 9, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year High - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 52-Week High - Time to Buy?January 8, 2025 | marketbeat.comState Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)State Street Corp raised its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 168.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,915 shares of the company's stocJanuary 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 29,846 SharesJanuary 3, 2025 | insidertrades.comNap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 29,846 shares of the company's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $25.54, for a total transaction of $762,266.84. Following the transaction, the insider now owns 10,656,172 shares in the company, valued at $272,158,632.88. This represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.January 2, 2025 | marketbeat.comFY2024 Earnings Estimate for NAMS Issued By HC WainwrightNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for NewAmsterdam Pharma in a research report issued on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($1.64)January 1, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationDecember 31, 2024 | msn.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 33,438 SharesDecember 31, 2024 | insidertrades.comNewAmsterdam Pharma initiated with a Buy at H.C. WainwrightDecember 30, 2024 | markets.businessinsider.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,438 Shares of StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $26.01, for a total value of $869,722.38. Following the transaction, the insider now owns 10,727,490 shares in the company, valued at approximately $279,022,014.90. This represents a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.December 30, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at HC WainwrightHC Wainwright began coverage on NewAmsterdam Pharma in a research note on Monday. They set a "buy" rating and a $48.00 price objective for the company.December 30, 2024 | marketbeat.comNap B.V. Forgrowth Sells 25,132 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockDecember 27, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $640,614.68 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the company's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $25.49, for a total transaction of $640,614.68. Following the sale, the insider now directly owns 10,777,092 shares of the company's stock, valued at $274,708,075.08. This represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.December 26, 2024 | marketbeat.comNap B.V. Forgrowth Sells 49,772 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 49,772 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $25.60, for a total transaction of $1,274,163.20. Following the completion of the transaction, the insider now owns 10,802,224 shares of the company's stock, valued at approximately $276,536,934.40. The trade was a 0.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.December 26, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of "Buy" by AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target priDecember 26, 2024 | marketbeat.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 100,728 Shares of StockDecember 21, 2024 | insidertrades.comNap B.V. Forgrowth Sells 100,728 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the transaction, the insider now owns 10,908,502 shares in the company, valued at approximately $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.December 20, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for NAMS Q1 Earnings?NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of NewAmsterdam Pharma in a report released on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.20) peDecember 20, 2024 | marketbeat.comQ4 Earnings Forecast for NAMS Issued By Leerink PartnrsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a report issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings of (December 19, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's What HappenedDecember 18, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 4.7% - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.7% Higher - Still a Buy?December 17, 2024 | marketbeat.comNap B.V. Forgrowth Sells 166,011 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockDecember 17, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 SharesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares of the company's stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.December 16, 2024 | marketbeat.comNewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesDecember 13, 2024 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Here's What HappenedNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Here's WhyDecember 13, 2024 | marketbeat.comNewAmsterdam Pharma’s $452.6M Public Offering SuccessDecember 13, 2024 | tipranks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.97 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 1,231.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 239,December 13, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Fmr LLCFmr LLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 35.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 330,412 shares of the company's stock after purchasing an additional 86,712 shares duringDecember 13, 2024 | marketbeat.comNewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol DrugDecember 12, 2024 | msn.comNewAmsterdam Pharma Stock Hits 90-Plus RS RatingDecember 12, 2024 | yahoo.comNewAmsterdam Pharma price target raised to $47 from $35 at ScotiabankDecember 12, 2024 | markets.businessinsider.comNewAmsterdam Pharma prices $416M stock offeringDecember 12, 2024 | seekingalpha.comNewAmsterdam Pharma Co NV Announces Pricing of Public OfferingDecember 12, 2024 | gurufocus.comNewAmsterdam Pharma 12.12M share Secondary priced at $24.50December 11, 2024 | tipranks.comNewAmsterdam Pharma Co NV Announces Pricing of Public OfferingDecember 11, 2024 | gurufocus.comNewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsDecember 11, 2024 | globenewswire.comNewAmsterdam Pharma: Positive Obicetrapib Data Leads To New CatalystsDecember 11, 2024 | seekingalpha.comNewAmsterdam Pharma: Positive Obicetrapib Data Leads To New CatalystsDecember 11, 2024 | seekingalpha.comEsperion selloff continues following competitor data from NewAmsterdamDecember 11, 2024 | tipranks.comNewAmsterdam Pharma announces $300M offering of ordinary shares, warrantsDecember 11, 2024 | markets.businessinsider.comNewAmsterdam Pharma Co NV Announces $300 Million Public OfferingDecember 10, 2024 | gurufocus.comNewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsDecember 10, 2024 | globenewswire.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.650.72▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼74▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Roivant Sciences News Revolution Medicines News Lantheus News Blueprint Medicines News BridgeBio Pharma News Legend Biotech News Elanco Animal Health News Cytokinetics News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
